As of November 14, 2026, Keenova Therapeutics plc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 20, 2026 to February 24, 2026 (Form 8-K, February 24, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Keenova Therapeutics plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Keenova Therapeutics plc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-20 to 2026-02-24. Every row below is cited to the filing it comes from, and this page adds each new change as Keenova Therapeutics plc files it.
Layoffs on record: 1 filing or notice, latest 2024-01-09 (layoff filings and notices).
Also on the record for Keenova Therapeutics plc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | Stake report, Schedule 13D/A, by GoldenTree Asset Management LP | 22.4% of the class | 5%+ stakes | Source |
| October 6, 2026 | Stake report, Schedule 13D/A, by GoldenTree Asset Management LP | 21.3% of the class | 5%+ stakes | Source |
| May 22, 2026 | Stake report, Schedule 13D/A, by Silver Point Capital, L.P. | 15.2% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by MARATHON ASSET MANAGEMENT GP, L.L.C. | 6.8% of the class | 5%+ stakes | Source |
| April 17, 2026 | Stake report, Schedule 13D/A, by Silver Point Capital, L.P. | 14.2% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G, by Hein Park Capital Management LP | 5.5% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G/A, by Hudson Bay Capital Management LP | 5.19% of the class | 5%+ stakes | Source |
| December 10, 2025 | Stake report, Schedule 13D/A, by Silver Point Capital, L.P. | 11.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by MARATHON ASSET MANAGEMENT GP, L.L.C. | 7.7% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13D/A, by Silver Point Capital, L.P. | 10.7% of the class | 5%+ stakes | Source |
| August 7, 2025 | Stake report, Schedule 13D, by GoldenTree Asset Management LP | 20.2% of the class | 5%+ stakes | Source |
| August 7, 2025 | Stake report, Schedule 13G/A, by Hudson Bay Capital Management LP | 6.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Keenova Therapeutics plc now and the warning signs.
Free to see. No signup.
Keep reading
More on Keenova Therapeutics plc and the records around it.
Keenova Therapeutics plc elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- MARATHON ASSET MANAGEMENT GP, L.L.C. also filed stake reports on 2 other companies: GRAFTECH INTERNATIONAL LTD (May 2026)
- GoldenTree Asset Management LP also filed stake reports on 4 other companies: QVC GROUP, INC. (Oct 2026), GoldenTree Opportunistic Credit Fund (Jun 2026), United Parks & Resorts Inc. (Feb 2026)
- Silver Point Capital, L.P. also filed stake reports on 9 other companies: Smart Share Global Limited (Aug 2026), Cool Company Ltd. (May 2026), Veradigm Inc. (May 2026)
Watch Keenova Therapeutics plc
Get an email when Keenova Therapeutics plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Keenova Therapeutics plc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Keenova Therapeutics plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Keenova Therapeutics plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-24 | Reported | not named in the filing | 8-K, 2026-02-24 | ||
| 2026-02-20 | Reported | not named in the filing | 8-K, 2026-02-20 |
New leaders reset buying decisions — get the Full Report on Keenova Therapeutics plc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Keenova Therapeutics plc, with the record behind each one.
Find candidates like senior executive at Keenova Therapeutics plcEvery change, in the filing's words
Reported
The Employment Agreement provides that Mr. Olafsson will be restricted from soliciting the Company's employees and business partners during the 12-month period following his termination of employment for any reason (the " Restricted Period ").
- On February 23, 2026, ST Shared Services LLC, a subsidiary of Keenova Therapeutics plc (the "Company"), entered into the Fourth Amended and Restated Employment Agreement (the "Employment Agreement") with Sigurdur (Siggi) Olafsson.
- The Prior Agreement provided that during the first half of 2026 Mr. Olafsson and the Company would discuss in good faith entering into a longer-term employment agreement.
- Pursuant to the Employment Agreement, Mr. Olafsson will remain in his role as Chief Executive Officer of ST Shared Services LLC and the Company until January 1, 2028 (the "Expiration Date"), and will be appointed as Chair of the Company's Board of Directors (the "Board") not later than May 14, 2026, provided that if a successor Chief Executive Officer is appointed prior to the Expiration Date, Mr. Olafsson's role will transition to Executive Chair of the Board ( "Executive Chair" ).
- If ST Shared Services LLC and Mr. Olafsson do not mutually agree to extend the term of Mr. Olafsson's employment prior to the Expiration Date, Mr. Olafsson's service as Chief Executive Officer, Chair and/or Executive Chair, as applicable, of the Company shall automatically terminate on the Expiration Date, which termination shall constitute a termination by the Executive with Good Reason (as defined in the Employment Agreement).
Reported
In accordance with the terms of the Plan, the Award Forms set forth terms and conditions applicable to particular awards, including with respect to vesting and the treatment of awards in various termination scenarios and changes in control.
- The Plan provides for the grant of stock options, stock appreciation rights, restricted stock, restricted units ("RSUs"), deferred stock units and other stock-based awards.
- On February 18, 2026, the Board adopted a form of award agreement for RSUs to be granted under the Plan (the "Form of RSU Award") and a form of award agreement for performance-based awards to be granted under the Plan (the "Form of PSU Award", collectively the "Award Forms").
- The Form of PSU Award includes various operating, financial and strategic performance measures that could be used to evaluate performance.
- Those performance measures may include, at the discretion of the Board or the Human Resources and Compensation Committee of the Board, as the case may be, criteria selected to measure the level of performance of the Company, including over a specified period.
- In particular, vesting may be based on the satisfaction of one or more organizational, financial or strategic goals, applied to either the Company as a whole or to a business unit or subsidiary, either individually, alternatively or in any combination, and that are absolute or relative to the performance of one or more comparable companies or an index of comparable companies.
Tools for this story
Each opens in a new tab, filled in for Keenova Therapeutics plc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
